



08 April 2021

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Notification of Investor Webinar: NanaBis™ Phase III Trial Design

Highlights:

- Following IND acceptance, the NanaBis™ Phase III study protocol has been published on US ClinicalTrials.gov website (www.clinicaltrials.gov)
- Marks further progress towards initiation of Phase III trial
- Medlab to host webinar on the Phase III trial design and objectives

Medlab (ASX.MDC) an Australian biotech using delivery platforms to enhance medicines, particularly in the field of oncology, is pleased to advise that the study protocol for its NanaBis™ Phase III study has been published on US ClinicalTrials.gov website (www.clinicaltrials.gov).

The protocol for the study titled “NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers”; Identifier NCT04808531 can be viewed at <https://bit.ly/3vVgEFb>.

Medlab will host a webinar for interested parties on the finalised trial design and objectives:

When: Apr 22, 2021 10:00 AM Canberra, Melbourne, Sydney
Topic: NanaBis™ Phase III Trial Design Webinar

Register in advance for this webinar:

<http://www.medlab.co/asx>

After registering, you will receive a confirmation email containing information about joining the webinar.

Medlab CEO Dr Sean Hall said, “The published clinical trial protocol marks another step towards initiation of the trial, which will commence later this year. We invite interested parties to participate in the webinar for an overview of the study design and endpoints, and to illustrate why Medlab is one of the most advanced medicinal cannabis candidates for the treatment of pain, pursuing an FDA regulatory pathway.”

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab – www.medlab.co

Medlab Clinical is an Australian-based, ASX listed biotech using delivery platforms to enhance medicines, particularly in the field of oncology. In pain management, Medlab is developing cannabis-based medicines. Its lead candidate NanaBis™ equimolar comprising of THC: CBD, is being developed as non-opioid alternative for the treatment of cancer-induced bone pain and has IND approval to enter Phase III clinical trials.

Medlab’s proprietary drug delivery platform NanoCelle® is used to enhance a wide range of active ingredients, with commercial opportunities in pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. Medlab’s products are proudly validated by research and supported by a growing patent portfolio. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised to deliver more for human health and beyond.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 - sean_hall@medlab.co	Kyahn Williamson, WE Communications T: + 61 0401018828 - kwilliamson@we-worldwide.com
---	--